The novel coronavirus is still all over the news, especially since we are in the middle of the 4th wave of the pandemic. The vaccines against the disease are also remaining in the headlines and now, we are addressing the one from Pfizer.
Check out the available data below.
Pfizer said on Monday that a Phase 2/3 trial showed its Covid-19 vaccine was safe and generated a “robust” antibody response in children ages 5 to 11.
CNN revealed also the fact that these are the first such results released for this age group for a US Covid-19 vaccine.
Pfizer said it plans to submit to the US FDA for emergency use authorization soon.
Pfizer could authorize vaccine in weeks
FDA officials explained that after the data is submitted, the agency could authorize a vaccine for younger children in a matter of weeks.
According to the latest reports coming from CNN, this trial included 2,268 participants, and it’s also worth noting the fact that it used a two-dose regimen of the vaccine administered 21 days apart.
CNN also said that this trial used a 10-microgram dose (which is smaller than the 30-microgram dose that has been used for those 12 and older.)
Here’s what Pfizer said:
“The 10 microgram dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age.”
Pfizer also stated that the levels compared well with older people who received the larger dose, demonstrating a “strong immune response in this cohort of children one month after the second dose.”
“Further, the COVID-19 vaccine was well tolerated, with side effects generally comparable to those observed in participants 16 to 25 years of age.”
Another issue that’s worth mentioning is that Pfizer’s spokesperson also confirmed that were no instances of myocarditis – just in case you don’t know, this is a type of heart inflammation that has been linked with mRNA vaccines.
